Botanix Pharmaceuticals reports robust early sales and expanding prescriber engagement for Sofdra™, its FDA-approved topical gel for excessive underarm sweating, signaling promising growth ahead.
- AUD 25 million gross sales since January 2025
- Over 2,300 unique prescribers in June with refill rates above industry average
- More than 16,000 prescriptions filled across 6,700 patients
- Strategic expansion of sales territories underway to accelerate growth
- High patient adherence supported by Botanix Fulfilment Platform
Strong Launch Performance
Botanix Pharmaceuticals has delivered an encouraging update on the commercial rollout of Sofdra™, its topical gel for primary axillary hyperhidrosis. Since its launch in early 2025, Sofdra has generated approximately AUD 25 million in gross sales, reflecting steady month-over-month growth. This performance aligns with the trajectories seen in recent successful dermatology product launches, underscoring Sofdra’s market acceptance.
Expanding Prescriber Base and Patient Engagement
The number of healthcare professionals prescribing Sofdra continues to rise, with over 2,300 unique prescribers recorded in June alone. This expanding prescriber base is complemented by refill rates that surpass industry averages, indicating strong patient satisfaction and ongoing use. Since launch, more than 16,000 prescriptions have been filled for approximately 6,700 patients, with those starting treatment early averaging 3.4 refills compared to the typical two refills per year seen in the topical medication category.
Strategic Growth Investments
Botanix is actively investing to accelerate Sofdra’s market penetration. The company has expanded its sales territories from 27 to 33 in the first quarter of fiscal 2026 and plans to increase to 50 territories across five regions by the second quarter. This expansion is supported by additional regional managers and enhanced sales materials aimed at healthcare practitioners to stimulate patient inquiries and awareness. Botanix also maintains a digital presence through telehealth platforms and a speaker program to educate clinicians, further bolstering Sofdra’s profile.
Patient Adherence and Fulfilment
Patient adherence rates are notably high, with a 95% adherence rate among those enrolled in the auto-refill program and 79% adherence across all patients. This reflects a positive patient experience and the effectiveness of the Botanix Fulfilment Platform in supporting ongoing treatment. Sofdra’s gross-to-net yield is also trending positively, reaching 23% by June and targeting a range comparable to leading US dermatology companies.
Outlook
Botanix’s Executive Chairman Vince Ippolito expressed satisfaction with Sofdra’s launch trajectory, emphasizing expectations for continued growth. With strategic investments and strong early market indicators, Sofdra appears well-positioned to deepen its foothold in the dermatology space, offering a novel solution for patients with limited treatment options for excessive underarm sweating.
Bottom Line?
Sofdra’s promising launch momentum sets the stage for Botanix’s next growth phase amid expanding market reach.
Questions in the middle?
- How will Botanix sustain and scale Sofdra’s prescriber engagement amid increasing competition?
- What impact will the planned expansion to 50 sales territories have on overall sales growth?
- How might patient adherence trends evolve as Sofdra reaches a broader demographic?